Thrombopoietin TRIZ Cases
- Humanized RAG/Il2rg Knockout Mice for Granuloma Infection Models
Humanized IL-3/GM-CSF knockout mice sustain human hematopoietic cells and form human immune granulomas for pathogen infection studies.
- Bi-Functional FLT3 Ligand Fusion Polypeptides for Short Half-Life
A thrombopoietin-FLT3 ligand fusion polypeptide extends circulation time while boosting platelet production and hematopoietic cell survival.
- Fc-Peptide Fusion Protein Purification for Sulfide Variant Removal
A staged affinity, mixed-mode, and cation exchange sequence removes sulfide variants from refolded Fc-peptide fusion proteins while preserving yield.
- Albumin-Free HSC Culture Medium Using PVA and PI3K Activation
PVA and PI3K activators enable albumin-free, serum-free expansion of human hematopoietic stem cells while maintaining CD34+ populations.
- Humanized Cytokine Mice for Human HSC Engraftment
Poor human HSC support limits mouse models; RAG/Il2rg knockouts and humanized cytokines sustain engraftment for immune-response testing.
- Recombinant MPL Ligand for Megakaryocyte Stimulation
Isolated MPL ligand resolves thrombocytopenia treatment gaps by enabling precise factor identification and reliable platelet production.
- Thermoregulated Fc-peptide Production in Prokaryotic Host Cells
A thermoregulated expression system using a mutant cI857 repressor induces Fc-peptide fusion protein synthesis via mild temperature shifts.
- Thrombopoietin Ligand Activating Mpl Receptor for Thrombocytopenia
Thrombopoietin mediates megakaryocyte maturation via mpl receptors, resolving inadequate platelet counts in thrombocytopenia.
- MPL Ligand Recombinant Production for Thrombocytopenia
Recombinant MPL ligand stimulates megakaryocyte proliferation, addressing ineffective glucocorticoid treatments for thrombocytopenia.
- Thrombopoietic Compounds for Bone Healing
TPO-coated scaffolds promote robust bone healing with less heterotopic bone formation than BMP-2.
- Dimerized TMP-HSA Fusion Protein for Platelet Production
A dimerized TMP-TMP-HSA fusion protein extends plasma half-life through covalent disulfide bonds formed by a dedicated dimerization domain.